|Dr. Jean-Paul Kress M.D.||Chairman of Management Board, MD & CEO||1.91M||N/A||1965|
|Mr. Sung H. Lee||CFO & Member of Management Board||483.12k||N/A||1970|
|Dr. Marlies Sproll||Special Adviser to the Chief Exec. Officer||N/A||N/A||1958|
|Mr. Klaus De Wall||Head of Accounting & Tax||N/A||N/A||N/A|
|Ms. Lara Smith Weber||Head of Controlling, Corp. Fin. & Corp. Devel.||N/A||N/A||N/A|
|Dr. Margit Urban||Head of Discovery Alliances & Technologies||N/A||N/A||N/A|
|Dr. Anja Pomrehn||Sr. VP & Head of Investor Relations||N/A||N/A||N/A|
|Ms. Charlotte Lohmann||Sr. VP of Legal, Compliance & IP and Gen. Counsel||N/A||N/A||1970|
|Mr. Thomas Biegi||VP & Head of Corp. Communications||N/A||N/A||N/A|
|Ms. Maria Castresana||Sr. VP & Global Head of HR||N/A||N/A||N/A|
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.
MorphoSys AG’s ISS governance QualityScore as of 1 October 2022 is 1. The pillar scores are Audit: 2; Board: 1; Shareholder rights: 1; Compensation: 3.